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Background: Animal studies show that peripheral inflammatory stimuli may activate microglial cells in the brain
implicating an important role for microglia in sepsis-associated delirium. We systematically reviewed animal
experiments related to the effects of systemic inflammation on the microglial and inflammatory response in the brain.
Methods: We searched PubMed between January 1, 1950 and December 1, 2013 and Embase between January 1,
1988 and December 1, 2013 for animal studies on the influence of peripheral inflammatory stimuli on microglia and
the brain. Identified studies were systematically scored on methodological quality. Two investigators extracted
independently data on animal species, gender, age, and genetic background; number of animals; infectious stimulus;
microglial cells; and other inflammatory parameters in the brain, including methods, time points after inoculation, and
brain regions.
Results: Fifty-one studies were identified of which the majority was performed in mice (n = 30) or in rats (n = 19).
Lipopolysaccharide (LPS) (dose ranging between 0.33 and 200 mg/kg) was used as a peripheral infectious stimulus in 39
studies (76 %), and live or heat-killed pathogens were used in 12 studies (24 %). Information about animal characteristics
such as species, strain, sex, age, and weight were defined in 41 studies (80 %), and complete methods of the disease
model were described in 35 studies (68 %). Studies were also heterogeneous with respect to methods used to assess
microglial activation; markers used mostly were the ionized calcium binding adaptor molecule-1 (Iba-1), cluster of
differentiation 68 (CD68), and CD11b. After LPS challenge microglial activation was seen 6 h after challenge and
remained present for at least 3 days. Live Escherichia coli resulted in microglial activation after 2 days, and heat-killed
bacteria after 2 weeks. Concomitant with microglial response, inflammatory parameters in the brain were
reviewed in 23 of 51 studies (45 %). Microglial activation was associated with an increase in Toll-like receptor
(TLR-2 and TLR-4), tumor necrosis factor alpha (TNF-α), and interleukin 1 beta (IL-1β) messenger ribonucleic acid
(mRNA) expression or protein levels.
Interpretation: Animal experiments robustly showed that peripheral inflammatory stimuli cause microglial
activation. We observed distinct differences in microglial activation between systemic stimulation with
(supranatural doses) LPS and live or heat-killed bacteria.
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The peripheral immune system has a strong effect on
the brain as exemplified by the high incidence of delir-
ium and the strongly increased risk for the development
of dementia after systemic infections [1, 2]. In rodent ex-
periments, peripheral challenge with lipopolysaccharide
(LPS) caused a steep increase of brain tumor necrosis
factor alpha (TNF-α) that can persist for months [3–9].
Peripheral (systemic) LPS challenge activates microglia,
the major active immune cells in the central nervous
system. Microglia can be in a resting state (morphologic-
ally “ramified”) or an activated state (morphologically
“amoeboid”) [10]. Resting microglia survey their envir-
onment for damage, ready to support endangered neu-
rons or to interfere with a potential threat to the tissue
integrity. Danger signals may trigger these surveying
microglia and cause transformation to activated states,
referred to as the M1 and M2 phenotypes [11]. M1 acti-
vated microglia produce pro-inflammatory mediators
and are assumed to act as neurotoxic cells [11, 12], while
M2 activation is induced by signals from apoptotic cells
and have a role in remodeling and repair [11–13].
Sepsis in humans has also been associated with micro-
glial activation [14]. Previously, we postulated that im-
paired cholinergic inhibitory control of microglia in elderly
people, and to a greater extent in patients with (incipient)
neurodegenerative disorders, contributes to uncontrolled
neuro-inflammation [15]. High concentrations of pro-
inflammatory mediators released by M1 activated microglia
are potentially neurotoxic and might not only cause acute,
reversible, behavioral effects, such as delirium, but also lead
to persistent detrimental effects through bystander damage
to neighboring neurons [16, 17]. The microglial response
drifts out of control and ultimately causes neurodegenera-
tion [1, 18]. This cycle might account for why neurobehav-
ioral occurrences can persist in elderly patients after
recovery from sepsis and after systemic cytokine produc-
tion has fallen. This information inspired the formulation
of a neuro-inflammatory hypothesis explaining the associ-
ation of systemic infection, chronic central nervous system
inflammation, and poor outcome, where microglial cells
play a key role. Animal studies on systemic inflamma-
tion and microglial reaction support this hypothesis,
but studies vary widely in setup and interpretation of
results. In this review, we summarize available evidence
on the effect of different systemic inflammatory stimuli
on timing and intensity of the microglial reaction.
Methods
Search strategy
We searched PubMed between January 1, 1950 and
December 1, 2013 and Embase between January 1, 1988
and December 1, 2013 for animal studies using peripheral
inflammatory stimuli and evaluating the effect of thesestimuli on microglia, using search terms “microglia” AND
“animal model” NOT “review”. We also searched the
reference lists of articles identified by this search strategy
and selected those that we judged to be relevant. Two
independent observers reviewed articles for inclusion and
exclusion criteria, and differences were resolved by
discussion.
Selection of articles
Studies were included if they fulfilled the following cri-
teria: (1) the study described an experiment where a per-
ipheral infectious stimulus was administrated in animals,
in vivo; (2) the study assessed the effects on microglia in
the brain; (3) the effects on microglia were determined
with specific microglial markers; (4) a group of control
animals was described; (5) the study was an original full
paper which presented unique data; and (6) the studies
were published in English, French, or German. Reasons
for exclusion of an article were as follows: (1) any ma-
nipulation in or around the brain before, during, or after
the peripheral infectious stimulus; (2) the use of a
neurotropic pathogen; (3) the use of a chemical synthetic
infectious stimulus; (4) animal models in which the in-
fectious stimulus reached the brain and caused second-
ary meningitis; (5) the use of transgenic animal models
for a specific (brain) disease; and (6) animal models
where the infectious stimulus was given intra-uterine.
Full text articles of selected studies were obtained for
further evaluation. Two independent observers extracted
data and resolved differences by discussion.
Data extraction
Each study was scored for key issues, such as animal
species, gender, age, and genetic background; number of
animals in treated and control groups; method of dos-
age, site of inoculation, and kind of infectious stimulus
that was administrated; the effect of peripheral infectious
stimulus on microglial cells in the brain; and methods of
how this effect was determined on which time point
after inoculation and in which region of the brain this
effect was examined. The quality of studies was judged
by a risk of bias assessment, scoring external and in-
ternal validity for each study [19].
Definition of microglial activation
Microglial cells were defined as activated based on the fol-
lowing criteria: (1) microglia showed an activated morph-
ology based on immunohistochemical staining; (2) there
was a significant increase in number and/or size of micro-
glia compared to the control group; and (3) there was a
significant increase in expression of a microglial marker.
When all three criteria were negative, microglia were in-
active. If one or more criteria were positive, microglia were
activated. If results were contradictory (e.g., increased
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negative) microglia were judged as moderately activated.
Results
Description of studies
In total, 2950 publications were identified and 149 were se-
lected for further review (Fig. 1); 29 publications met inclu-
sion criteria and 22 additional articles were identified in a
reference search, so 51 publications were included in this
systemic review. There was considerable variation in
animal species and stimuli. The majority of studies was
performed in mice (n = 30) or in rats (n = 19). LPS was
used as a peripheral infectious stimulus in 39 studies
(76 %), and live or heat-killed pathogens were used in
12 studies (24 %).
Information about animal characteristics such as
species, strain, sex, age, and weight was defined in 41
studies (80 %), and methods of the disease model were
described in 35 studies (68 %). Four studies lacked de-
scription of animal characteristics and disease model.
Just one study described treatment allocation as ran-
domized and evaluation in a blinded fashion [20].
None of the studies provided power calculations for
animal group sizes, reported baseline measurements of
animals between groups, or handling of outlined or
missing data.Fig. 1 Study selection processOutcome parameters
Microglial response was the main outcome parameter in
all studies; the state of microglia was defined by immuno-
histochemistry in 36 studies (70 %), by the combination of
immunohistochemistry, and respectively, quantitative
polymerase chain reaction (qPCR) in two studies (4 %),
Western blot in two studies (4 %), or in situ hybridization
in one study (2 %); six studies used qPCR (12 %), three
flow cytometry (6 %), and one study Western blot (2 %) to
define microglial activation.
The most commonly used marker of microglial activa-
tion was the ionized calcium-binding adaptor molecule 1
(Iba-1), either as sole marker (n = 20), or in combination
with cluster of differentiation 68 (CD68; n = 2), Griffonia
symplicifolia isolectin B4 (IB4; n = 1), or macrophage re-
ceptor with collagenous structure (MARCO; n = 1).
CD11b was used in 14 studies, and 5 of these studies
combined CD11b with CD68, major histocompatibility
complex II (MCHII), Toll-like receptors 2 and 4 (TLR-2,
TLR-4), and F4/80. In three other studies, TLR-2 was
stated as an activation marker of microglial cells after
identifying the cells with CD45 and CD11b antibodies by
flow cytometry or in combination with Iba-1. One study
used TLR-2 with qPCR while MHCII expression between
groups was similar [21]. The markers CD68 (n = 5), F4/80
(n = 2,) and IB4 (n = 2) were also used as sole markers.
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was the hippocampus. Several studies restricted their
interest to the hippocampal area (n = 17). Eight studies
evaluated the hippocampal area in combination with other
brain regions: cortex (n = 8), substantia nigra (n = 2), cere-
bellum (n = 2), thalamus (n = 1), striatum (n = 1), mid-
brain (n = 1). Five studies were limited to the cortical
areas. Four studies homogenized the hemispheres for
flow cytometry analysis or qPCR. The remainder 16
studies (25 %) evaluated other brain regions, and brain
regions were not specified in one study.
Secondary outcomes were inflammatory mediators in
the brain, for example cytokines, chemokines, Toll-like
receptors (TLRs), or markers for damage or death, and
were evaluated in 37 studies (73 %). Behavioral studies
were performed in 14 studies (27 %).
Infectious stimuli
Lipopolysaccharide
A single-dose of LPS was evaluated in wild-type mice in
20 studies (Table 1). LPS was administered intraperito-
neally in 19 studies and subcutaneously in one study.
Mice were male in 16 of 20 studies (80 %) and varied
with respect to age and genetic background. The major-
ity of studies used LPS derived from Escherichia coli (E.
coli) (12 of 20 studies [60 %]), four studies used LPS
from Salmonella ssp., and four studies did not report the
LPS origin. The dose of LPS ranged between 0.33 and
200 mg/kg, with 1 and 5 mg/kg both used in seven stud-
ies. Microglial response was evaluated 1 h to 1 year after
LPS injection.
Two studies described activation of microglia 6 h after
inoculation, 11 of 12 studies (92 %) showed microglial ac-
tivation 1 day after inoculation, and three studies found
microglial activation 3 days after challenge. Findings impli-
cate that a single LPS challenge activates microglia 6 h
after challenge and that the activation remains for at least
3 days. Five studies evaluated microglial response after this
period: three studies showed no microglial activation after
1 week, 5 weeks, and 5 months, while another study re-
ported moderately activated microglia after 3 months.
One study showed microglial activation 1 year after LPS
challenge (Table 1). Importantly, overall, the interpret-
ation of the results was hampered by lack of informa-
tion. The number of animals was noted in only 13 of 20
studies (65 %), and a statistical test comparing microglial
response in LPS challenged and control groups were pro-
vided in 10 studies (50 %). LPS challenges in experiments
using knockout mice were described in four studies, all
using intraperitoneal injection, and are discussed below in
the separate sections (Appendix) [22–25].
A single LPS challenge in rats was evaluated in eight
studies. LPS was given intraperitoneally (63 %) or intra-
venously (37 %; Table 1), and seven studies used LPSfrom E. coli. LPS origin was not mentioned in one study.
Dose of LPS ranged between 0.002 and 10 mg/kg. In
general, microglia start to become moderately active 3 h
after LPS challenge, reaching their activation state after
8 h to 2 days, and return to their normal resting state
after 7 days.
Sequential LPS challenges were evaluated in nine studies
(Table 2); seven studies used mice and two studies rats.
Five of nine studies (56 %) were done in mice with a
C57BL/6 genetic background, and age of these animals
varied between 5 weeks and 10 months. LPS from E. coli
was used in six of the nine studies; origin of LPS was not
mentioned in three studies. Dose of LPS ranged from 0.05
to 4 mg/kg. Animals were challenged between 2 and 48
times over a period of 1 day to 6 months with total LPS
dose ranging from 0.1 to 56 mg/kg. Eight of these nine
studies showed microglial activation (89 %); however, the
majority of time points evaluated after 1 month showed
only moderate or no microglial activation.
One study administered LPS 1 mg/kg intraperitoneally
in 6-month-old male gerbils, prompting a moderate
microglial response at day 4 [26]. Another study evaluated
the effect of serial intraperitoneal injections of 0.2 mg/kg
LPS at different stages of brain development in opossums
(on postnatal day [P] P14, P35, and P42) [27]. At day 10
after the first LPS injection, immunohistochemistry re-
vealed microglial activation in younger age groups (P14
and P35) but not in older animals (P42) [27].
Lipoteichoic acid
One study evaluated intravenous administration of 20
mg/kg lipoteichoic acid (LTA) from Staphylococcus aur-
eus (strain L2515) in rats [28]. Two days after challenge,
microglial cells were activated as shown by enhanced
immunoreactivity for CD11b and MHCII as compared
to the unchallenged group, 2 days after LTA challenge.
In these experiments, CD68 immunoreactivity of the
pineal microglia appeared unaltered, while challenge
with LPS (0.05 mg/kg) induced enhancement of CD68
immunoreactivity in addition to response for morph-
ology, CD11b, and MHCII expression.
Bacteria
Bacteria were used as systemic challenge in 12 of 51
studies (24 %; Table 3). Animal species were rats in the
majority of studies (75 %). Live bacteria were used in
seven studies (58 %) and heat-killed bacteria in five stud-
ies (42 %). E. coli (American Type Culture Collection
(ATCC) 15746) was most commonly used as systemic
challenge with live bacteria (86 %); other live bacteria
administered were Salmonella typhimurium. The heat-
killed bacteria that were used were Mycobacterium tu-
berculosis and Mycobacterium butyricum, also referred
to as complete Freund’s adjuvant (CFA).
Table 1 Single challenge with lipopolysaccharide (LPS) in mice and rats
Study Genetic
background
N Age/weight Sex Type of LPS Site of LPS Dose (mg/kg) Time of termination Microglial activation
Mice
Henry [33] BALB/c 6 3 m M E. coli (O127:B8) ip 0.33 1 day Yes
Henry [21] BALB/c 7 3–4 m M E. coli (O127:B8) ip 0.33 4 h Yes
18–20 m 4 h Yes
Carnavale [58] C57BL/6 4 12–15 w M S. equine abortus ip 0.5 1 day Yes
5 weeks No
Terrando [22] C57BL/6 4 12–14 w M E. coli (O111:B4) ip 1 1 day Yes
3 days Yes
1 week No
Chung [36] ICR 7 6 w M U ip 1 6 h Yes
12 h Yes
1 day Yes
Chen [25] C57BL/6 4 8–12 w M E. coli (O55:B5) ip 1 1 day No
Laflamme [3] CD1 U 20–25 gr M E. coli (O55:B5) ip 1 U Yes
Gao [59] B6C3F1/J U 7 m M E. coli (O111:B4) ip 1 1 day Yes
5 months No
Okuyama [41] ICR 10 6 w M S. typhimurium ip 1 3 days Yes
Kaushik [60] BALB/c U 6–8 w U S. enterica ip 5 1 day Yes
Hwang [61] C57BL/6 U 11 w M E. coli (O55:B5) ip 5 3 days Yes
Qin [7] B6:129SF2 U 8 w M E. coli (O111:B4) ip 5 2 h Yes
C57BL/6 U 3 h Yes
Sierra [6] p7.2fms-EGFP U 2 m B S. typhimurium ip 5 1 day Yes
Masocha [62] C57BL/6 8 8–12 w U E. coli (O111:B4) ip 5 4 h No
1 day Yes
1 year Yes
Ha [63] C57BL/6 5 7 w M U ip 5 3 h Yes
O’Callaghan [40] C57BL/6 4 8–10 w M E. coli (O111:B4) ip 5 1 day Yes
3 months Moderate
Bhaskar [23] C57BL/6 U 2 m U U ip 1 1 day Moderate
10 1 day Yes




Smithason [20] C57BL/6 6 10–12 w M U ip 200 2 days Moderate
Sehgal [8] C57BL/6 15 2–3 m M E. coli (O55:B5) sc 3 12 h Yes
Rats
Monje [64] Fisher 344 3 160–180 gr F U ip 1 1 week Yes
Fan [39] Sprangue-Dawley 6 5 d B E. coli (O55:B5) ip 2 1 day Yes
Wang [65] Sprangue-Dawley 3 280–300 gr M E. coli (O55:B5) ip 5 1 day Yes
Semmler [66] Wistar 4 250–300 gr M E. coli (O127:B8) ip 10 4 h No
8 h No
1 day Moderate
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Table 1 Single challenge with lipopolysaccharide (LPS) in mice and rats (Continued)
Semmler [5] Wistar 5 250–300 gr M E. coli (O127:B8) ip 10 1 day Yes
Garcia-Bueno [67] Sprangue-Dawley 5 260–340 gr M E. coli (O55:B5) iv 0.002 1–3 h Moderate*
Jiang-Shieh [28] Wistar 10 200–250 gr M E. coli (O55:B5) iv 0.05 2 days Yes
Buttini [44] Sprangue-Dawley 2 180–200 gr M E. coli (O55:B5) iv 1 1 day No*







Column time of termination is the time from the (first) LPS challenge
Abbreviations: N number of animals per group, m months, wk weeks, d days, gr gram, U unknown, M male, F female, B both sexes, ip intraperitoneal, sc
subcutaneous, iv intravenous, iv intravenous
*Did not express data in statistical values, no statistical information
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fect of systemic infectious challenge in early life. In these
studies, infant rats (P4) were challenged with E. coli 1x
105 colony-forming units (CFU)/g subcutaneously. Im-
munohistochemistry with Iba-1 revealed activated
microglia in the hippocampus 2 days after challenge andTable 2 Multiple intraperitoneal challenges with lipopolysaccharide
Study Genetic
background
N Age Sex Type of LPS
Mice
Frank-Cannon [38] C57BL/6 3 6–13 w U E. coli (O111:B4)
Katafuchi [68] C57BL/6 8 10 m M U
Lee [52] ICR 5 5 w M U
Nguyen [34] C57BL/6 U 6 m U E. coli (O55:B5)
Franciosi [46] FVB/N 5 5 m B U
8 m
Chen [25] C57BL/6 4 8–12 w M E. coli (O55:B5)
Shankaran [69] C57BL/6 5 10–15 w F E. coli (O111:B4)
Rats
Yin [70] Sprangue-Dawley 4 3 d M E. coli (O55:B5)
Wu [9] Sprangue-Dawley 8 10 w M E. coli (U)
Column time of termination is the time from the (first) LPS challenge. All challenges
Abbreviations: N number of animals per group, U unknown, M male, F female, B bo
2 weeks, q.wk once a week, q.a.d. every other day, b.i.w. 2 times a week
*Did not express data in statistical values, no statistical informationincreased CD11b expression in the hippocampus area up
to 3 months after infection. Another study using S. typhi-
murium (SL3261; 106 CFU) showed increased expression
of CD11b and CD68 in the thalamus 7 days after the chal-
lenge. Interestingly, CD11b and CD68 expression returned
to baseline levels 3 weeks after challenge. At all time(LPS) in mice and rats






0.1 b.i.w. 16× 1.6 2 months No
0.1 b.i.w. 24× 2.4 3 months Yes*
0.1 b.i.w. 48× 4.8 6 months No
0.25 q.d. 7× 1.75 7 days Yes
0.25 q.d. 7× 1.75 18 days Yes
1 q.2wk. 6× 6 15 weeks No*
1 q.wk. 4× 4 4 weeks Yes
16× 16 17 weeks Yes
1 q.d. 2× 2 3 days Moderate*
4× 4 5 days Yes
0.3 q.a.d. 4× 1.2 7 days No
1 q.a.d. 4× 4 7 days Yes
4 q.a.d. 4× 16 7 days Yes
4 q.a.d. 14× 56 4 weeks Yes
0.05 q.a.d 2× 0.1 6 days Yes
18 days Yes
42 days No
1.2 q.d. 14× 16.8 1 week Yes
were intraperitoneal
th sexes, m months, w weeks, d days, gr gram, q.d. every day, q.2wk once every
Table 3 Challenge with pathogens in mice and rats
Study Genetic
background
N Age/weight Sex Pathogen Site of challenge Dose
Mice
Püntener [43] C57BL/6 3 >8 w F S. typhimurium (SL3261) ip 1 × 106 CFU 1 day No
7 days Moderate
21 days No
Rabchevsky [31] C57BL/6 6 6 w F CFA sc + ipl 150 ug 14 days No
21 days No
Di Filippo [32] Biozzi ABH 4 6–8 w F CFA sc + ipl 100 ug U Yes
Rats
Bland [71] Sprangue-Dawley 8 4 d M E. coli (ATCC 15746) sc 1 × 105 CFU/g 2 days Yes
70 days Yes
98 days Yes
Williamson [72] Sprangue-Dawley 9 4 d M E. coli (ATCC 15746) sc 1 × 105 CFU/g 2–3 months Yes
Bilbo [73] Sprangue-Dawley 6 4 d M E. coli (ATCC 15746) sc 1 × 105 CFU/gram 2 months No*
16 months Yes
Bilbo [42] Sprangue-Dawley 8 4 d M E. coli (ATCC 15746) sc 1 × 105 CFU/g 56 days Yes
Bilbo [35] Sprangue-Dawley 6 4 d M E. coli (ATCC 15746) sc 1 × 105 CFU/g 56 days No






Raghavendra [4] Sprangue-Dawley 4 175–200 gr M CFA ipl 100 ul 4 h Moderate
4 days Yes
2 weeks Yes
Liu [30] Lewis 6 2 m F Heat-killed M. butyricum id 1.5 mg 3 weeks Moderate*
12 m Yes
Wu [29] Lewis 6 100–110 gr F Heat-killed M. butyricum id 25 mg/kg 2 weeks Yes
3 weeks Yes
4 weeks Yes
Column time of termination is the time from the (first) LPS challenge
Abbreviations: U unknown, F female, m months, d days, ip intraperitoneal, ipl intraplantar, M male, B both sexes, w weeks, gr gram, sc subcutaneous, id
intradermal, N number of animals per group, CFA complete Freund’s adjuvant
*Did not express data in statistical values, no statistical information
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logical ramified with fine processes.
Studies evaluating challenge with heat-killed bacteria
used CFA, a solution composed of heat-killed and dried
mycobacteria (usually M. butyricum and/or M. tubercu-
losis). Injecting CFA intradermal or intraplantar induces
adjuvant arthritis, a model of chronic peripheral inflam-
mation. One study showed CD11b messenger ribonucleic
acid (mRNA) expression in brainstem and forebrain 4 h, 4
days, and 2 weeks after CFA challenge [4]. Another study
challenging rats with 25 mg/kg CFA showed cortical
microglial activation immunohistochemistry with Iba-1 2,3, and 4 weeks after inoculation [29]. One study evaluated
the role of age and compared rats of two and 12 months
old, using 1.5 mg challenge of CFA, showing morphologic-
ally activated microglia revealed in the CA1 region of the
hippocampus for both age groups, three weeks after chal-
lenge [30]. However, no CD68 or IL-1β-positive microglial
cells were detected in the brains of 2-month-old rats,
while the expression of CD68 and IL-1β was significantly
increased in hippocampal CA1 region of 12-month-old
rats compared to control rats.
CFA is also used to induce experimental allergic en-
cephalomyelitis (the EAE model), an animal model for
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tissue homogenized with these heat-inactivated myco-
bacteria. Only the control groups (CFA) could be in-
cluded in the current review. One mouse study showed
no microglial activation in the brainstem up to 3 weeks
after inoculation with 150 ug CFA [31]. Another mouse
study using 100 ug CFA on days 1 and 7 showed acti-
vated microglia in the CA1 region of the hippocampus
22 days after the last challenge [32].
Inflammatory parameters
Inflammatory parameters were reviewed if they were
evaluated concomitantly with the microglial response.
This was done in 23 of 51 studies (45 %).
Toll-like receptors
Seven studies evaluated TLRs on microglia, by qPCR,
immunohistochemistry, in situ hybridization, or flow cy-
tometry: four evaluated TLR-2 expression [3, 21, 33, 34]
and three TLR-4 expression [4, 35, 36]. Three studies de-
scribed TLR-2 upregulation [3, 21, 33] and two TLR-4
upregulation [4, 36]. Microglial activation was associated
with TLR upregulation independent of type of challenge
(LPS, E. coli, or CFA) or time point of evaluation. In
those studies showing resting microglia after challenge,
TLR expression was not different from the control
group. One study challenged TLR-4 knockout mice with
serial LPS injections of 1 mg/kg every day for 4 days,
showing decreased microglial activation in the knockout
mice as compared to wild-type animals (Appendix) [25].
Although TLR-2 is known for its recognition of lipopep-
tides, peptidoglycans (PGN), and LTA, all of which are
cell wall components of gram-positive bacteria, TLR-2
upregulation was found after LPS challenge [3, 21, 33].
One study using a head-to-head comparison between
LPS, PGN, and LTA challenges showed a profound tran-
scriptional activation of TLR-2 only after LPS.
Cytokines and chemokines
TNF-α protein levels or mRNA expression were deter-
mined in 14 studies [3–9, 29, 32, 34, 37–40], by qPCR,
ELISA, western blot, in situ hybridization, and immuno-
histochemistry, at 23 different time points after the chal-
lenge. Microglial activation was associated with increased
expression of TNF-α in the brain, as compared to con-
trols, at 12 time points: ranging from 3 h to 1 day after
single LPS (n = 5), after multiple LPS (n = 1), or after a
CFA challenge (n = 6). At four time points, microglial acti-
vation was described without increased TNF-α protein
levels: 1 day after single LPS (n = 1), 1 and 3 days after E.
coli (n = 2), or 22 h after CFA challenge (n = 1). One study
observed an elevation of TNF-α mRNA and protein levels
30 min after a single LPS challenge [7], and this effect
remained up to 10 months after the LPS administration.Interestingly, the studies evaluating E. coli challenge
showed no differences in TNF-α concentration as com-
pared to the control group, independent of whether or not
microglia were activated [37].
Interleukin 1 beta (IL-1β) protein levels or mRNA ex-
pression were determined in 16 studies [4–6, 8, 9, 21, 22,
30, 32, 35, 37, 39–43], at 24 different time points after
challenge. At 13 time points microglial activation was
present in combination with increased IL-1β protein levels
or mRNA expression patterns, from 4 h to 1 week after
LPS challenge (n = 7), from 1 and 56 days after E. coli
challenge (n = 2), and from 4 h to 3 weeks after CFA chal-
lenge (n = 4). At three time points, microglia were acti-
vated but no IL-1β increase was measured; 1 day after LPS
(n = 1), 2 days after E. coli (n = 1), and 22 h after CFA
challenge (n = 1). In studies showing microglia in resting
or moderately activated states, brain IL-1β levels were
comparable to that of the control group (n = 7). IL-1 re-
ceptor (IL-1R) knockout mice were used in one study,
evaluating a single dose of 1 mg/kg of LPS (Appendix)
[22], and IL-1R knockouts had no microglial activation in
the CA1 region of the hippocampal area, in contrast to
the wild-type group. IL-1R antagonist (IL-1Ra) injection in
wild-type mice just before the LPS challenge also pre-
vented microglial activation, suggesting an important role
of IL-1 in the activation of microglia.
Interleukin 6 (IL-6) protein levels or mRNA expres-
sion were determined in seven studies [4–6, 8, 9, 22, 37],
at 17 different time points after challenge. At five time
points, microglial activation was present in combination
with increased protein levels or mRNA expression pat-
terns, at 12 h and 1 week after a single LPS (n = 2) and
at 4 h, 4 days, and 2 weeks after CFA challenge (n = 3).
At five time points, microglia were activated but brain IL-
6 levels were similar to controls: 1 day after single LPS
(n = 3) and 1 and 3 days after E. coli challenge (n = 2).
Animals challenged with E. coli had similar IL-6 con-
centration as compared to the controls, independent of
whether microglia were activated (n = 2) or not (n = 3).
Interleukin 10 (IL-10) protein levels or mRNA expres-
sion were determined in seven studies [5, 6, 8, 21, 29, 37],
at 12 different time points after challenge. At four time
points, microglia were activated in combination with in-
creased protein levels or mRNA expression patterns: 4 h
and 1 day after systemic LPS (n = 2) and 3 and 4 weeks
after CFA challenge (n = 2). At four time points, microglia
were activated but brain IL-10 levels were similar to
controls: 1 day after LPS (n = 1), 1 and 3 days after E.
coli (n = 2), and 2 weeks after CFA challenge (n = 1).
One study showed microglial activation after LPS chal-
lenge but decreased levels of IL-10 in the brain [8].
Two studies measured transforming growth factor beta
(TGF-β) mRNA expression with qPCR 1 day after a sin-
gle LPS challenge [5, 6]. Microglial cells were activated
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mRNA expression and found increased concentrations
[5]. The other study measured TGF-β in isolated micro-
glia and found no differences between challenged and
control groups [6]. Two studies measured monocyte
chemotactic protein 1 (MCP-1) mRNA expression in the
brain [5, 8], showing that microglial activation was asso-
ciated with MCP-1 upregulation. Fractalkine receptor
(CX3CR1) knockout mice were used in two studies
evaluating a single dose of 10 mg/kg LPS [23] and mul-
tiple LPS challenges (20 ug for 4 days) (Appendix) [24].
One day after the (last) LPS challenge, immunohisto-
chemistry with Iba-1 revealed enhanced microglial acti-
vation in the hippocampal area of the CX3CR1
knockout mice as compared to wild-type animals.
Blood–brain barrier
The blood–brain barrier (BBB) was examined in eight
studies [27, 28, 31, 36, 37, 44–46]. Four studies showed
disruption of the BBB (challenge was LPS in two studies,
either intraperitoneal or intravenous, E. coli subcutane-
ously in one study and CFA intraperitoneal in the other
study) [28, 31, 37, 45], three studies showed intact BBB
(challenge was LPS in all three studies, either intraperito-
neal [n = 2] or intravenous [n = 1]) [36, 44, 46], and one
study showed inconclusive results (challenge was LPS)
[27]. Studies were highly variable with respect to methods
used to define the integrity of the BBB (fluorescent so-
dium, protein and fibrinogen extravasation, exogenous
horseradish peroxidase, Evans blue dye, ribosomal ribo-
nucleic acid (rRNA) of E. coli, fluorescent LPS, and the in-
vasion by blood monocytes or macrophages).
Discussion
Experimental studies have shown that peripheral inflam-
matory stimuli, such as LPS, cause a profound immuno-
logical response in the brain resulting in microglial
activation. After a single challenge of LPS, microglia were
moderately active within 3 h after administration, reaching
their profound activation state after 8 h to 2 days and sub-
sequently return to their normal resting state after 7 days.
Interestingly, cytokine expression levels in the brain and
activation markers may remain elevated for months after a
single LPS challenge. These experiments also showed that
systemic challenge with live bacteria, mainly the gram-
negative bacteria E. coli and S. typhimurium, causes
microglial activation. A gram-negative bacterium contains
approximately 10−15 g of LPS, which implicates that the
LPS dosages used in the included animal studies are
supernatural. Consequently, the microglial response of
challenge with bacteria is less profound as compared to
that found in the experiments using a challenge with
supernatural LPS doses. LPS as a peripheral inflammatory
challenge is much easier to use than live bacteria: there isno waiting for bacteria to be cultured, no monitoring of
bacteria to grow in midlog phase, and no time is lost with
harvesting, wash and dilute the bacteria in the right
amount. In addition, there is no danger of contamination,
and therefore, the laboratory and animal facility do not
have to comply with special safety matters. However, be-
cause of the differences in microglial response between a
peripheral challenge with LPS or live bacteria, the clinical
relevance of using LPS in these animal models is question-
able. Experimental studies using live bacteria suggest an
important role of age in the process of microglial activa-
tion after systemic challenge, although further research is
needed to confirm this. The observed effects support the
central role of microglial response in the development of
sepsis-associated delirium and poor functional outcome
after sepsis, in particular in the elderly population [15].
The mechanisms connecting systemic inflammatory chal-
lenge and microglial activation remain unclear. Several
pathophysiological mechanisms have shown to play a role
in this process. Microglia may be activated through primary
autonomic afferents—in particular the vagal nerve—by ac-
tive BBB transport of pro-inflammatory chemo- and/or cy-
tokines, passive transport of pro-inflammatory products via
the circumventricular organs, or by signaling the epithelial
cells of the blood–brain barrier [47]. Microglial activation
was associated with upregulation of TLRs, independent of
type of challenge or time point of evaluation. In studies in
which microglial activation was not observed, TLR expres-
sion was not different from the control group [34, 35].
Moreover, microglia could not be activated in TLR re-
ceptor knocked-out mice [25]. Microglial activation
was associated with elevated levels of pro-inflammatory
mediators in the brain.
Age is an important intrinsic factor determining the
level of microglial activation after a systemic inflamma-
tory challenge. The normal aging process induces
changes in microglial phenotype, and these age-related
changes are also called “priming” [48]. Two studies com-
pared the effect of age on microglia after a peripheral
challenge [21, 30]. Systemic LPS challenges caused a
hyperactive microglial response in the brain of aged
mice, associated with higher induction of inflammatory
IL-1β and anti-inflammatory IL-10 [21]. Peripheral CFA
injection induced hippocampal microglial activation in
middle-aged rats and moderate activation in young rats.
In these experiments, microglial activation in middle-
aged rats was associated with neurocognitive deficits
[30]. Aging-induced immune senescence occurs in the
brain as age-associated microglial senescence, which
renders microglia to function abnormally and may even-
tually promote neurodegeneration.
Evidence suggests that microglia act neurotoxic when
fully activated (M1 phenotype) [49], whereas other stud-
ies show that activated microglia show more diversity
Table 4 Keypoints review
Keypoints
• Systemic challenge with LPS and live bacteria cause a profound
immunological response in the brain resulting in microglial activation.
• Microglial response after challenge with bacteria is less profound as
compared to challenge with LPS, which makes the clinical relevance of
using LPS in these animal models questionable.
• When defining microglial activation, researcher should not only focus on
proliferation and morphology, but also examine pro-and anti-inflammatory
markers indicating M1/M2 responses.
• Mechanisms connecting systemic inflammatory challenge and microglial
activation remain unclear, but age is an important intrinsic factor.
• Future experimental studies on studying systemic inflammation and
microglial response should do the following:
−use mouse models
−use live bacteria
−use standardized and quantitative measurements of microglial activation
−focus on the role of the aging brain
−apply with the current standards of animal experiments
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(M2 phenotype) [50, 51]. The M1 immune response of
microglia is triggered by the activation of TLRs via
pathogen-associated molecular patterns (PAMPs) or
intracellular proteins released from damaged neurons;
other M1 triggers are complement 1q (C1q) and adeno-
sine triphosphate (ATP) released from astrocytes in re-
sponse to neuronal injury [11, 12]. These activated M1
microglia produce the pro-inflammatory mediators
TNF-α, IL-1β, and IL-6 [11, 12]. M2 activation is in-
duced by signals from apoptotic cells that activate trig-
gering receptor expressed by myeloid cells-2 (TREM2)
such as heat shock protein 60 (Hsp60), or by anti-
inflammatory cytokines, such as interleukin 14 (IL-14) and
interleukin 13 (IL-13). M2-activated microglia have a role
in remodeling and repair, triggering anti-inflammatory re-
sponses via release of TGF-β and IL-10 [11–13]. While be-
yond the scope of this review, several studies show an
association between systemic LPS challenge, microglial ac-
tivation, and cognitive deficits in mice [52–55]. These
studies demonstrate that systemic LPS challenge causes
cyclooxygenase-1 (COX-1), COX-2, and inducible nitric
oxide synthase (iNOS) expression in the brain, which is
hypothesized to cause susceptibly to cognitive deficits in
mice [52, 53, 55]. Regarding these facts, it is imperative—
when it comes to defining microglial activation—to focus
not only on proliferation and morphology but also examine
pro- and anti-inflammatory markers on or around micro-
glia. If more homogeneous data on these inflammatory
markers, in relation to microglial activation, would be
available, then bigger steps can be made in understanding
the pathogenesis in why neuro-inflammation occurs when
a systemic challenge is administrated. However, less than
half of the studies (45 %) included in this review contain
data on inflammatory mediators. When microglia were ac-
tivated, an increase in TLR-2, TLR-4, TNF-α, and IL-1β
mRNA expression or protein levels in the brain was seen
in most studies. A few studies examined anti-inflammatory
markers IL-10 (n = 6), TGF-β (n = 2), and MCP-1 (n = 2).
Studies have shown that microglial cells express various
neurotransmitter receptors [56], and neurotransmitters
could also exert pro- and anti-inflammatory effects on
microglial cells. For example, ionotropic glutamate re-
ceptors (iGluRs) can modulate TNF-α release, gamma-
amino-butytric acid (GABA) receptors modulate IL
release (IL-6 and IL-12) and adrenergic, dopaminergic,
and cholintergic receptors exhibit anti-inflammatory
effects [57]. These receptors add another challenge on
the pathogenesis on neuro-inflammation and should
not be ignored.
Heterogeneity among the included 51 studies hampered
the opportunity for a synthesis, e.g., quantitatively, in this
systematic review. Studies investigated several animal spe-
cies and inflammatory stimuli at different time points. Lackof adequate experimental description, power calculations
for animal group sizes, reported baseline measurements of
animals between groups, or handling of outlined or miss-
ing data further limited generalization of the results.
Nevertheless, this review provides a valuable overview of
current knowledge.Conclusion
Experimental studies have shown that peripheral chal-
lenge with LPS causes a profound immunological re-
sponse in the brain resulting in microglial activation, but
systemic challenge with live bacteria causes microglial
activation as well. However, the microglial response of
challenge with bacteria is less profound as compared to
that found in the experiments using a challenge with
supernatural LPS doses. The mechanisms connecting
systemic inflammatory challenge and microglial activa-
tion remain unclear, but age is an important intrinsic
factor determining the level of microglial activation after
a systemic inflammatory challenge. Heterogeneity among
the included studies hampered the opportunity for a
synthesis, e.g. quantitatively, in this systematic review.
Future experimental studies should opt for mouse
models, use live bacteria as well as standardized and
quantitative measurements of microglial activation, for
example, with flow cytometry, and focus on the role of
the aging brain. These studies should apply with the
current standards of animal experiments [19]. For opti-
mal external validation, experimental studies should in-
vestigate the role of aging on microglial activation
following a systemic infection with live bacteria, analo-
gous to the human situation: the clinical problem of
long-term poor outcome of sepsis-associated delirium in
elderly patients (Table 4).
Hoogland et al. Journal of Neuroinflammation  (2015) 12:114 Page 11 of 13AppendixTable 5 Intraperitoneal challenge with lipopolysaccharide (LPS) in knock-out mice
Study Knock out
gene
N Age Sex Type of LPS Dose Time of termination Microglial activation Compared to wild-type
Bhaskar [23] CX3CR1−/− U 2 m U U 10 mg/kg 1 d Yes* More*
Terrando [22] IL-1R−/− 4 12–14 w M E. coli (O111:B4) 1 mg/kg 1 d No Less*
3 d No Less*
1 w No Same*
Cardona [24] CX3CR1−/− U U U U 20 ug q.d. 2× 4 d Yes* More*
Chen [25] TLR4−/− 4 8–12 w M E. coli (O55:B5) 1 mg/kg q.d. 2× 4 d No* Less*
Column time of termination is the time from the (first) LPS challenge. All challenges were intraperitoneal
Abbreviations: U unkown, m months, d days, M male, w weeks, q.a.d every other day, N number of animals per group
*Did not express data in statistical values, no statistical informationAbbreviations
ATCC: American Type Culture Collection; ATP: adenosine triphosphate;
BBB: blood–brain barrier; C1q: complement 1q; CD11b: cluster of
differentiation 11b; CD45: cluster of differentiation 45; CD68: cluster of
differentiation 68; CFA: complete Freund’s adjuvant; CFU: colony-forming
units; COX-1: cyclooxygenase-1; COX-2: cyclooxygenase-2; CX3CR1: fractalkine
receptor; E. coli: Escherichia coli; GABA: gamma-amino-butytric acid;
Hsp60: heat shock protein 60; IB4: Griffonia symplicifolia isolectin B4; Iba-
1: ionized calcium-binding adaptor molecule 1; iGluRs: ionotropic glutamate
receptors; IL-10: interleukin 10; IL-13: interleukin 13; IL-14: interleukin 14; IL-
1R: interleukin-1 receptor; IL-1Ra: interleukin-1 receptor antagonist; IL-
1β: interleukin 1 beta; IL-6: interleukin 6; iNOS: inducible nitric oxide synthase;
LPS: lipopolysaccharide; LTA: lipoteichoic acid; M. butyricum: Mycobacterium
butyricum; M. tuberculosis: Mycobacterium tuberculosis; MARCO: macrophage
receptor with collagenous structure; MHCII: major histocompatibility complex
II; MCP-1: monocyte chemotactic protein 1; mRNA: messenger ribonucleic
acid; MS: multiple sclerosis; P: postnatal day; PAMPs: pathogen-associated
molecular patterns; PGN: peptidoglycans; qPCR: quantitative polymerase
chain reaction; rRNA: ribosomal ribonucleic acid; S. typhimurium: Salmonella
typhimurium; TGF-β: transforming growth factor beta; TLR: Toll-like receptor;
TLR-2: Toll-like receptor 2; TLR-4: Toll-like receptor 4; TLRs: Toll-like receptors;
TNF-α: tumor necrosis factor alpha; TREM2: triggering receptor expressed by
myeloid cells-2.
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